Zoptarelin doxorubicin

Drug Profile

Zoptarelin doxorubicin

Alternative Names: AEZS-108; AN-152; D-81858; Doxorubicin-GnRH agonist conjugate; ZEN-008

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Tulane University
  • Developer AEterna Zentaris Inc; National Cancer Institute (USA); University of Southern California
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Endometrial cancer

Highest Development Phases

  • Phase III Endometrial cancer
  • Phase II Breast cancer; Ovarian cancer
  • Phase I/II Prostate cancer
  • Discontinued Urogenital cancer

Most Recent Events

  • 12 Oct 2016 Zoptarelin doxorubicin sub-licensed to Specialised Therapeutics Asia in Australia and New Zealand
  • 01 Aug 2016 Zoptarelin doxorubicin sub-licensed to Rafa Laboratories in Israel and Palestinian Territories
  • 01 Jul 2016 AEterna Zentaris and Cyntec agree to co-promote and co-develop zoptarelin doxorubicin in Taiwan and Southeast Asia for endometrial cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top